Agios Pharmaceuticals (AGIO) Retained Earnings (2012 - 2026)
Agios Pharmaceuticals (AGIO) posted Retained Earnings of -$660.8 million for Q1 2026, down 17.64% on a QoQ basis from -$561.7 million in Q4 2025, and down 177.41% year-over-year from $853.7 million in Q1 2025.
Agios Pharmaceuticals (AGIO) Retained Earnings (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals' Retained Earnings history runs 15 years deep, the most recent figure standing at -$660.8 million for Q1 2026.
- Quarterly Retained Earnings fell 177.41% year-over-year to -$660.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$660.8 million (down 177.41% YoY) and the FY2025 annual result came in at -$561.7 million, down 277.18% from the prior year.
- Retained Earnings was -$660.8 million for Q1 2026 at Agios Pharmaceuticals, down from -$561.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$52.4 million in Q3 2024 and bottomed at -$1.0 billion in Q2 2024.
- A 5-year average of -$520.2 million and a median of -$507.1 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 1181.15% — and 2024, when it soared 92.79%.
- Agios Pharmaceuticals' Retained Earnings stood at -$470.6 million in 2022, then sank by 74.82% to -$822.6 million in 2023, then soared by 81.9% to -$148.9 million in 2024, then plunged by 277.18% to -$561.7 million in 2025, then fell by 17.64% to -$660.8 million in 2026.
- Business Quant data shows AGIO's Retained Earnings at -$660.8 million in Q1 2026, -$561.7 million in Q4 2025, and -$453.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Agios Pharmaceuticals | 2.13 Bn | 2.13 Bn | 19.43 Mn | -660.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -660.82 Mn |
| Dec 31, 2025 | -561.71 Mn |
| Sep 30, 2025 | -453.67 Mn |
| Jun 30, 2025 | -350.23 Mn |
| Mar 31, 2025 | -238.21 Mn |
| Dec 31, 2024 | -148.92 Mn |
| Sep 30, 2024 | -52.40 Mn |
| Jun 30, 2024 | -1.00 Bn |
| Mar 31, 2024 | -904.20 Mn |
| Dec 31, 2023 | -822.65 Mn |
| Sep 30, 2023 | -726.71 Mn |
| Jun 30, 2023 | -635.39 Mn |
| Mar 31, 2023 | -551.58 Mn |
| Dec 31, 2022 | -470.56 Mn |
| Sep 30, 2022 | -507.09 Mn |
| Jun 30, 2022 | -425.34 Mn |
| Mar 31, 2022 | -333.53 Mn |
| Dec 31, 2021 | -238.76 Mn |
| Sep 30, 2021 | -144.13 Mn |
| Jun 30, 2021 | -55.37 Mn |